Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The mitophagy and mitochondrial fission machinery is a sophisticated quality control system essential for maintaining cellular health by regulating mitochondrial number, morphology, and integrity [1, 3, 6]. Mitochondrial fission, primarily mediated by the GTPase Dynamin-related protein 1 (DRP1), facilitates the segregation of damaged or dysfunctional mitochondrial segments from the healthy network [1, 13, 20]. These segregated fragments are subsequently targeted for selective degradation via mitophagy, a specialized form of autophagy [3, 12, 17]. The canonical mitophagy pathway is governed by the PINK1 kinase and the E3 ubiquitin ligase Parkin, which sense mitochondrial depolarization and mark the organelle for engulfment by autophagosomes [2, 12, 16]. Dysregulation of this machinery is a hallmark of various pathologies, particularly neurodegenerative diseases like Parkinson's, where the accumulation of damaged mitochondria leads to oxidative stress and neuronal death [2, 7, 17]. In cancer, the machinery can play dual roles, either promoting tumor survival under stress or inducing mitophagic cell death [3, 5, 11]. Therapeutic strategies currently under development include small-molecule inhibitors of mitochondrial fission (e.g., DRP1 inhibitors) and enhancers of mitophagy (e.g., USP30 inhibitors or PINK1 activators) to restore mitochondrial homeostasis and prevent disease progression [1, 7, 19].
Modulation of mitochondrial dynamics and quality control through the inhibition of fission proteins (e.g., DRP1) or the activation of mitophagy-inducing proteins (e.g., PINK1, Parkin) and inhibition of deubiquitinating enzymes (e.g., USP30) [1, 2, 7, 19].
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitophagy and mitochondrial fission machinery.